Lifeboat Foundation

Researchers said the reason for this is because of “remarkable advances” in medical research and cancer prevention, detection, diagnosis and treatment. Between August 1, 2021 and July 31, 2022, for example, the Food and Drug Administration approved eight new anticancer therapeutics, 10 already approved therapeutics for use for new cancer types and two new diagnostic imaging agents.

“We have now a revolution in immune therapies. And when you put that together with the combination of targeted therapies, chemo and radiation therapy, we now have patients that would have died within two years of a diagnosis living 15, 20, 25, 30 years, essentially cured of their malignancies,” AACR President Lisa Coussens said.

However, this progress is not equal, and many populations “continue to shoulder a disproportionate burden of cancer,” the report says.

Mild, persistent inflammation in tissue is considered one of the biological hallmarks of the aging process in humans—and at the same time is a risk factor for diseases such as Alzheimer’s or cancer. Prof. Francesco Neri and Dr. Mahdi Rasa of the Leibniz Institute on Aging—Fritz Lipmann Institute (FLI) in Jena have succeeded for the first time in describing at the molecular level the regulatory network that drives the general, multiple-organ inflammatory response. Moreover, they were able to show that dietary restriction can influence this regulatory circuit, thereby inhibiting inflammation.

Inflammation is an immune response of the body that is, in itself, useful: our immune system uses it to fight pathogens or to remove damaged cells from tissue. Once the immune cells have done their work, the inflammation subsides: the infection is over, the wound is healed. Unlike such acute inflammations, age-related chronic inflammation is not local. The innate immune system ramps up its activity overall, resulting in chronic low-grade inflammation. This aging-related inflammation is also known as inflammaging.

Summary: In mice genetically more susceptible to PTSD following a stressful event, researchers found an increased expression of cortisol receptors on neurons in the CA1 region of the dorsal hippocampus. Those increased receptors enabled an elevated expression of the HCN1 protein and TRIP8b, reducing neural excitability.

Source: medical college of georgia at augusta university.

Social avoidance is a common symptom of PTSD, and scientists working to better understand why have laboratory evidence that while stress hormone levels consistently increase in the immediate aftermath of a traumatic event, there can be polar opposite consequences in parts of the brain down the line.

Earlier this summer, Forrest Smith got some promising news. The Denver-based petroleum engineer, who works for the National Park Service, had read reports on a new diabetes medication called tirzepatide. Clinical trials had confirmed a potent side effect: Tirzepatide users could shed up to 20 percent of their body weight. Smith told me he spent his childhood cast as “the fat kid in school,” and his adulthood locked in a cycle of losing pounds and regaining them. Though he is not diabetic, he was aware that some doctors were prescribing the drug for weight loss and, feeling like he had nothing to lose, sought one out for treatment. He took his first weekly injection in July, and says it was like “a switch was flipped overnight.” Food cravings disappeared. When watching skinny friends eat, he used to wonder, “How do you not eat that entire plate of cookies in front of you?” That all changed. “One cookie? Totally doable.”

He now weighs 236 pounds, 24 pounds down from when he began the medication. Smith’s spouse and parents were so impressed with his progress that they decided to seek out tirzepatide, too. His young children have noticed that running around their garden now tires them out before their father. Since his first shot, Smith has been reaching deeper into his closet for clothes that will fit. “Hopefully,” he said, “I don’t find parachute pants—I don’t have to go that far back.”

Tirzepatide (marketed by Eli Lilly and Company as Mounjaro) first became available to the public in May of 2022, when it was approved by the FDA as a diabetes treatment. And while FDA approval for using the drug specifically for weight loss appears imminent, doctors have the authority to deviate from FDA mandates when prescribing drugs, and some have been writing scripts to treat obesity at their own discretion. “I’ve been very excited about these medicines,” said Dr. Melanie Jay, director of NYU Langone’s Comprehensive Program on Obesity. “[Obesity] has always been something that’s under-treated.” It might be the trickle that precedes a torrent—tirzepatide is just one in a class of new extremely effective weight loss drugs that threaten to upend the way we think about and treat obesity.

The technique had largely been limited to editing patients’ cells in the lab. New research shows promise for treating diseases more directly.

Chromosome-level engineering is a completely different beast: it’s like rearranging multiple paragraphs or shifting complete sections of an article and simultaneously hoping the changes add capabilities that can be passed onto the next generation.

Reprogramming life isn’t easy. Xiao Zhu’s DNA makeup is built from genetic letters already optimized by eons of evolutionary pressure. It’s no surprise that tinkering with an established genomic book often results in life that’s not viable. So far, only yeast have survived the rejiggering of their chromosomes.

The new study, published in Science, made the technology possible for mice. The team artificially fused together chunks from mice chromosomes. One fused pair made from chromosomes four and five was able to support embryos that developed into healthy—if somewhat strangely behaved—mice. Remarkably, even with this tectonic shift to their normal genetics, the mice could reproduce and pass on their engineered genetic quirks to a second generation of offspring.

The same AI engine that made computers even better at games like chess and Go could also boost new drug discoveries.

A proof-of-concept study published in the journal Scientific Reports outlines a water-activated disposable paper battery. According to the scientists, it could be used to power a broad variety of low-power, single-use disposable electronics, such as smart labels for tracking items, environmental sensors, and medical diagnostic devices, thereby minimizing their environmental impact.

The battery was developed by Gustav Nyström and colleagues, and it consists of at least one cell that is one centimeter squared and is made up of three inks that have been printed on a rectangular piece of paper. The paper strip is covered with sodium chloride salt, and one of its shorter ends has been dipped in wax.

One of the flat sides of the paper is printed with ink containing graphite flakes, which serves as the positive end of the battery (cathode). The other side is printed with ink containing zinc powder, which serves as the negative end of the battery (anode).

Most of us consider nightmares pretty harmless, but apparently, they can be a bad sign. According to research at the University of Birmingham, people who experience frequent bad dreams in middle age are more likely to be diagnosed with dementia later in life.

New research suggests nightmares may become common several years or even decades before the characteristic memory and thinking problems of dementia set in. The study will be published today (September 21, 2022) in The Lancet.

Founded in 1,823 by Thomas Wakley, The Lancet is a weekly peer-reviewed general medical journal. It is one of the world’s oldest, most prestigious, and best known general medical journals. The journal publishes original research articles, review articles (“seminars” and “reviews”), editorials, book reviews, correspondence, as well as news features and case reports. The Lancet has editorial offices in London, New York, and Beijing.